Dicerna Pharmaceuticals Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Dicerna Pharmaceuticals in the last twelve months. There are currently 5 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Dicerna Pharmaceuticals stock.
View analyst ratings for Dicerna Pharmaceuticals or view top-rated stocks.

Wall Street analysts have given Dicerna Pharmaceuticals a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Dicerna Pharmaceuticals wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Dicerna Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Dicerna Pharmaceuticals.

Dicerna Pharmaceuticals, Inc. (NASDAQ:DRNA) announced its quarterly earnings results on Thursday, May, 6th. The biopharmaceutical company reported ($0.39) EPS for the quarter, missing the consensus estimate of ($0.28) by $0.11. The biopharmaceutical company earned $47.60 million during the quarter, compared to analyst estimates of $59.56 million. Dicerna Pharmaceuticals had a negative net margin of 67.58% and a negative trailing twelve-month return on equity of 82.91%.
View Dicerna Pharmaceuticals' earnings history.

Dicerna Pharmaceuticals' stock was trading at $16.88 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, DRNA shares have increased by 115.2% and is now trading at $36.32.
View which stocks have been most impacted by COVID-19.

5 brokers have issued 1 year target prices for Dicerna Pharmaceuticals' shares. Their forecasts range from $34.00 to $48.00. On average, they anticipate Dicerna Pharmaceuticals' share price to reach $42.29 in the next twelve months. This suggests a possible upside of 16.4% from the stock's current price.
View analysts' price targets for Dicerna Pharmaceuticals or view top-rated stocks among Wall Street analysts.

35 employees have rated Dicerna Pharmaceuticals CEO Douglas M. Fambrough, Ph.D. on Glassdoor.com. Douglas M. Fambrough, Ph.D. has an approval rating of 99% among Dicerna Pharmaceuticals' employees. This puts Douglas M. Fambrough, Ph.D. in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Dicerna Pharmaceuticals include CureVac (CVAC), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Perrigo (PRGO), Biohaven Pharmaceutical (BHVN), I-Mab (IMAB) and Schrödinger (SDGR).
View all of DRNA's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Dicerna Pharmaceuticals investors own include Axsome Therapeutics (AXSM), Strongbridge Biopharma (SBBP), Amarin (AMRN), Exelixis (EXEL), Sorrento Therapeutics (SRNE), TG Therapeutics (TGTX), Arbutus Biopharma (ABUS), Gilead Sciences (GILD), Pfizer (PFE) and Advanced Micro Devices (AMD).

Dicerna Pharmaceuticals trades on the NASDAQ under the ticker symbol "DRNA."

Dicerna Pharmaceuticals' stock is owned by a number of institutional and retail investors. Top institutional shareholders include RTW Investments LP (9.71%), BlackRock Inc. (7.98%), Woodline Partners LP (2.31%), Price T Rowe Associates Inc. MD (2.20%), Loomis Sayles & Co. L P (2.07%) and UBS Group AG (1.79%). Company insiders that own Dicerna Pharmaceuticals stock include Adam Koppel, Bain Capital Life Sciences Inv, Bob D Brown, Douglas Fambrough, James B Weissman, John B Green, Peter Kolchinsky, Regina M Paglia and Robert D Ciappenelli.
View institutional ownership trends for Dicerna Pharmaceuticals.

DRNA stock was sold by a variety of institutional investors in the last quarter, including Point72 Asset Management L.P., UBS Group AG, Renaissance Technologies LLC, Price T Rowe Associates Inc. MD, BNP Paribas Arbitrage SA, Assenagon Asset Management S.A., Panagora Asset Management Inc., and Prudential Financial Inc.. Company insiders that have sold Dicerna Pharmaceuticals company stock in the last year include Adam Koppel, Bob D Brown, James B Weissman, Regina M Paglia, and Robert D Ciappenelli.
View insider buying and selling activity for Dicerna Pharmaceuticals or view top insider-selling stocks.

DRNA stock was acquired by a variety of institutional investors in the last quarter, including Maverick Capital Ltd., Polar Capital Holdings Plc, Morgan Stanley, Bridger Management LLC, Compagnie Lombard Odier SCmA, Woodline Partners LP, Jennison Associates LLC, and JPMorgan Chase & Co..
View insider buying and selling activity for Dicerna Pharmaceuticals or or view top insider-buying stocks.

Shares of DRNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DRNA stock can currently be purchased for approximately $36.32.

Dicerna Pharmaceuticals has a market capitalization of $2.79 billion and generates $164.31 million in revenue each year. The biopharmaceutical company earns $-112,750,000.00 in net income (profit) each year or ($1.52) on an earnings per share basis.

Dicerna Pharmaceuticals employs 302 workers across the globe.

The official website for Dicerna Pharmaceuticals is www.dicerna.com.

Dicerna Pharmaceuticals is headquartered at 33 HAYDEN AVENUE, LEXINGTON MA, 02421.

Dicerna Pharmaceuticals' mailing address is 33 HAYDEN AVENUE, LEXINGTON MA, 02421. The biopharmaceutical company can be reached via phone at 617-621-8097 or via email at [email protected]